pSivida Corp. (PSDV) Earns Coverage Optimism Rating of 0.11
Media coverage about pSivida Corp. (NASDAQ:PSDV) has trended somewhat positive this week, Accern reports. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. pSivida Corp. earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.305116773926 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
pSivida Corp. (PSDV) opened at $1.26 on Monday. pSivida Corp. has a 1 year low of $1.03 and a 1 year high of $2.45.
pSivida Corp. (NASDAQ:PSDV) last posted its quarterly earnings data on Tuesday, November 7th. The company reported ($0.15) earnings per share for the quarter, hitting the consensus estimate of ($0.15). pSivida Corp. had a negative net margin of 226.31% and a negative return on equity of 139.56%. The firm had revenue of $0.39 million during the quarter, compared to analysts’ expectations of $0.74 million. sell-side analysts predict that pSivida Corp. will post -0.58 earnings per share for the current fiscal year.
PSDV has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of pSivida Corp. in a report on Wednesday, November 8th. Laidlaw initiated coverage on pSivida Corp. in a report on Wednesday, November 8th. They issued a “buy” rating and a $5.00 target price on the stock. Six analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average price target of $8.00.
About pSivida Corp.
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
Receive News & Ratings for pSivida Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.